These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31051317)

  • 1. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis.
    Besschetnova T; Brooks DJ; Hu D; Nagano K; Nustad J; Ominsky M; Mitlak B; Hattersley G; Bouxsein ML; Baron R; Lanske B
    Bone; 2019 Jul; 124():148-157. PubMed ID: 31051317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.
    Chandler H; Lanske B; Varela A; Guillot M; Boyer M; Brown J; Pierce A; Ominsky M; Mitlak B; Baron R; Kostenuik P; Hattersley G
    Bone; 2019 Mar; 120():148-155. PubMed ID: 30343166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia.
    Chandler H; Brooks DJ; Hattersley G; Bouxsein ML; Lanske B
    Osteoporos Int; 2019 Aug; 30(8):1607-1616. PubMed ID: 31053927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
    Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
    Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
    Doyle N; Varela A; Haile S; Guldberg R; Kostenuik PJ; Ominsky MS; Smith SY; Hattersley G
    Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
    Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G
    J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
    Varela A; Chouinard L; Lesage E; Guldberg R; Smith SY; Kostenuik PJ; Hattersley G
    Bone; 2017 Feb; 95():143-150. PubMed ID: 27894941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloading.
    Teguh DA; Nustad JL; Craven AE; Brooks DJ; Arlt H; Hu D; Baron R; Lanske B; Bouxsein ML
    Bone; 2021 Mar; 144():115801. PubMed ID: 33338664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture.
    Lanske B; Chandler H; Pierce A; Brown J; Ominsky M; Kostenuik P; Hattersley G
    J Orthop Res; 2019 Apr; 37(4):812-820. PubMed ID: 30790359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate.
    Khan MP; Singh AK; Singh AK; Shrivastava P; Tiwari MC; Nagar GK; Bora HK; Parameswaran V; Sanyal S; Bellare JR; Chattopadhyay N
    J Bone Miner Res; 2016 Mar; 31(3):615-29. PubMed ID: 26391310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice.
    Arlt H; Mullarkey T; Hu D; Baron R; Ominsky MS; Mitlak B; Lanske B; Besschetnova T
    Bone Rep; 2020 Dec; 13():100291. PubMed ID: 32637467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
    Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
    Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of parathyroid hormone on hypogonadism induced bone loss of proximal femur of orchiectomized rat.
    Tezval M; Serferaz G; Rack T; Kolios L; Sehmisch S; Schmelz U; Tezval H; Stuermer KM; Stuermer EK
    World J Urol; 2011 Aug; 29(4):529-34. PubMed ID: 21298272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
    Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA
    Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
    Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
    Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.
    Dempster DW; Zhou H; Rao SD; Recknor C; Miller PD; Leder BZ; Annett M; Ominsky MS; Mitlak BH
    J Bone Miner Res; 2021 Apr; 36(4):644-653. PubMed ID: 33434314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
    Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
    Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriparatide and Abaloparatide Have a Similar Effect on Bone in Mice.
    Brent MB; Stoltenborg FE; Brüel A; Thomsen JS
    Front Endocrinol (Lausanne); 2021; 12():628994. PubMed ID: 33953694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.